Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (120)	4/20/2001 9:13:32 AM
From: Cal Gary	Respond to of 132

DiagnoCure receives positive results from ImmunoCyt DiagnoCure Inc CUR Shares issued 17,498,032 Apr 18 close $2.00 Thu 19 Apr 2001 News Release Mr. Pierre Desy reports DiagnoCure has had positive clinical performance of ImmunoCyt when used in conjunction with cytology in the detection of upper urinary tract transitional cell carcinoma (UT-TCC). Dr. Michele Lodde, a member of the team led by the Prof. Michael Marberger, PhD, at the department of urology and clinical pathology at the University of Vienna, Austria, presented the results of this independent study at the European Association of Urology Convention in Geneva last week. Dr. Marberger is well respected within the international community of urologists and pathologists. This independent study involved 37 patients with symptoms and/or findings on imaging that are suggestive of upper tract cancer. The study assesses the value of ImmunoCyt in conjunction with cytology in detecting these tumours, mainly because of ImmunoCyt's high sensitivity to low-grade cancer. The combination of ImmunoCyt and cytology gives 88-per-cent sensitivity on voided specimens while providing 100-per-cent sensitivity and specificity on urine collected directly from the ureters. The study concluded that patients with upper tract cancer are at a high risk of later developing tumours of the bladder. Likewise, previous tumours of the bladder may be followed by upper tract manifestations of cancer. Up to 29 per cent of patients with high-risk superficial bladder tumours have been reported to develop upper tract cancer in 15 years. These results provide evidence in support of claims that the upper tract should be monitored following the initial diagnosis. "The high precision achieved with ImmunoCyt potentially reduces the need for more invasive instrumentation of the upper urinary tract in order to rule out the presence of tumours," said Dr. Marberger. During the same meeting, Dr. Marberger also presented the results from his department's use of ImmunoCyt in the followup of patients previously diagnosed with bladder cancer. "We are very satisfied with the sensitivity of ImmunoCyt to detect bladder tumour recurrences, which assists us in better managing our patients," Dr. Marberger added. (c) Copyright 2001 Canjex Publishing Ltd. stockwatch.com

To: Cal Gary who wrote (120)	4/22/2001 9:31:51 PM
From: Mr. L. Neufeldt	Read Replies (1) \| Respond to of 132

Well.... Suppose CUR has $1.4 million in the bonds coming due in August. Suppose they have a debt payment to the Quebec gov't for $1.4 million due in August. $1.4 - $1.4 = $0 in the bank. You can get this DD from the financial statements. Now suppose CUR has a little known resolution that states they can't raise additional monies through private placement shares less than $4.00 I've even suspected a bit of churning is taking place with Desjardin to create market volume. Ya never know! Of course this is all supposition. Also, a deal for uPM3 should be very close. Forecast numbers of revenues are also looking promising. This is college money for the kids. Plunk in and leave for 5 years, it should do very nicely. Especially at these numbers. I wouldn't mind a dip down to $1.30 again, but that may not happen. Anything else happening out there in the market I should be looking at?